GET DAILY SIGNALSSOPHiA GENETICS (SOPH) Delivers +25% Revenue Growth in Q3 While Narrowing Losses
Key Takeaways
- Third quarter revenue reached $24.3 million, up 25% year over year and slightly above consensus estimates near $23.9 million.
- Net loss per share was ($0.24), wider than the roughly ($0.13) consensus expectation but improved from ($0.30) a year earlier.
- Adjusted EBITDA loss narrowed 31% year over year to $6.1 million.
- The platform ran a record 118,000 analyses, and core genomic customers rose to 551 from 488 in the prior-year period.
- Management guided full-year 2026 revenue to the upper end of its $94–$96 million range and reaffirmed its positive adjusted EBITDA target for the second half of 2027.
- Liquid biopsy volumes more than doubled year over year, reinforcing a key growth catalyst.
Putting the Quarter in Context
SOPHiA GENETICS is an AI-native healthcare technology company whose SOPH DDM platform analyzes genomic and multimodal data to support cancer and rare-disease care. Its quarterly results are closely watched because they show whether revenue growth is translating into operating leverage and a clearer path to profitability. The company has delivered accelerating growth through 2026, but it remains unprofitable on an IFRS basis, making the trajectory of its adjusted EBITDA loss and its gross margin central to the investment case. With new products such as liquid biopsy and companion diagnostics ramping and biopharma collaborations expanding, this quarter offered investors a progress check on both the pace of adoption and the quality of the company's cost discipline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Reported Results
SOPHiA GENETICS reported third quarter 2026 revenue of $24.3 million, an increase of 25% year over year (26% on a constant currency basis) from $19.5 million a year earlier, modestly ahead of consensus. Platform analysis volume reached a record 118,000, up 19% year over year, with North America revenue up 41% and Asia-Pacific up 33%.
Adjusted gross margin came in at 72.8%, and the adjusted EBITDA loss narrowed 31% to $6.1 million. On an IFRS basis, however, the net loss was $20.3 million, essentially flat with $20.0 million a year ago, while the loss per share of ($0.24) improved from ($0.30) but came in wider than the roughly ($0.13) consensus estimate, partly reflecting share-based compensation, litigation, and warrant fair-value adjustments.
Management guided full-year 2026 revenue to the upper end of its $94–$96 million range and reaffirmed the adjusted EBITDA loss outlook of $29–$32 million, while reiterating a goal of positive adjusted EBITDA in the second half of 2027.
How the Market Responded
Heading into the report, sentiment had already turned more constructive, with shares trading well above their 200-day moving average. The third quarter showed a fundamental improvement that the headline EPS miss obscures: revenue beat estimates, net dollar retention improved to 118%, churn remained below 1%, and liquid biopsy and biopharma momentum continued to build. Still, investors are weighing a familiar tension. Operating losses were flat in dollar terms, and per-share improvement partly reflects a larger share count following equity raises. The result is a growth story that is scaling, but one where the benefits have not yet fully reached the bottom line shareholders own.
Looking Ahead: Key Factors to Monitor
The most important near-term signal is whether the company can sustain its revenue trajectory while continuing to narrow adjusted EBITDA losses. Management expects to convert a substantial portion of incremental revenue to the bottom line, and the reaffirmed target of positive adjusted EBITDA in the second half of 2027 makes profitability the central test for investors.
Several catalysts bear watching. Liquid biopsy adoption is ramping quickly, with volumes more than doubling year over year, and recent signings are expected to contribute meaningfully in the fourth quarter and into 2027. New biopharma collaborations, including companion diagnostic programs, could add high-value revenue, though their timing depends on implementation and ramp schedules.
On the risk side, investors should monitor the pace of U.S. growth, which decelerated from elevated levels, as well as foreign exchange effects and recurring items such as share-based compensation, litigation expense, and warrant fair-value adjustments that continue to weigh on reported results. The balance between reinvestment for growth and disciplined cost control will shape how quickly the company approaches breakeven. From what I see, this remains an important area to track closely.
Exploring AI Tools in My Research Process
I often turn to Tickeron’s AI Screener when evaluating earnings-driven names like this one. It lets me quickly filter across technical patterns, fundamentals, and industry peers to put the latest results in broader context and spot related opportunities without spending hours on manual screens. This kind of structured view helps me stay objective when weighing growth against the path to profitability.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SOPH's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for SOPH turned positive on October 26, 2026. Looking at past instances where SOPH's MACD turned positive, the stock continued to rise in 49 of 54 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SOPH's RSI Indicator exited the oversold zone, 14 of 17 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on SOPH as a result. In 104 of 119 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
Following a +5.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where SOPH advanced for three days, in 205 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
SOPH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
SOPH moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SOPH crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SOPH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for SOPH entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.282) is normal, around the industry mean (4.699). P/E Ratio (-6.129) is within average values for comparable stocks, (13.248). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (6.452) is also within normal values, averaging (6.065).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. SOPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SOPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement